Latest papers

Environmental causes of childhood brain tumours.

Chemotherapeutic choice of ranimustine or nimustine on the basis of regional polyamine levels in rat brain.

PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: a mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment.

Proline-linked nitrosoureas as prolidase-convertible prodrugs in human breast cancer cells.

Chemotherapy-induced bystander effect in response to several chloroethylnitrosoureas: an origin independent of DNA damage?

Preclinical studies of steroid-linked nitrosoureas in murine pancreatic adenocarcinoma PANO2.

[Accelerated postoperative chemoradiotherapy for malignant cerebral glioma].

Evaluation of dimethoxydop-NU as a novel anti-tumor agent.

[Fotemustine: muphoran]

Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.

VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.

Impressive objective response in a patient with extensive metastatic melanoma including the brain.

Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.

Interventional management of gastroduodenal lesions complicating intra-arterial hepatic chemotherapy.

Screening for ENU-induced mutations in mice that result in aberrant ethanol-related phenotypes.

The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas.

Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethylnitrosourea reveals drug efficacy and tumor adaptive metabolic pathways.

Structural basis for the adherence of Plasmodium falciparum-infected erythrocytes to chondroitin 4-sulfate and design of novel photoactivable reagents for the identification of parasite adhesive proteins.

[Clinical significance of mustoforan in management of malignant glioma].

The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive.